Demo Data from VLDB 2026 / reviewers in the wild / expert
Haohuai He
dblp:321/3069
· DBLP profile ↗
5ranked-venue papers
3as first author
5since 2021 · last 2024
0000-0003-3831-3996ORCID · corroborated
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 3 · 3 first-author · 3 since 2021Artificial intelligence and machine learning · 2 · 2 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
2 papers |
Bioinformatics and computational biology · 100% |
Topics — the 4 heaviest of 4, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery › drug-target interaction prediction
drug-target binding affinity prediction |
1.4 | 2 | 2024 | Integrating sequence and graph information for enhanced drug-target affinity prediction · Sci. China Inf. Sci. 2024 NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023 |
Bioinformatics and computational biology › drug discovery
drug-target interaction prediction |
0.8 | 1 | 2024 | Integrating sequence and graph information for enhanced drug-target affinity prediction · Sci. China Inf. Sci. 2024 |
Bioinformatics and computational biology
drug discovery |
0.7 | 1 | 2023 | NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023 |
Bioinformatics and computational biology › drug discovery
drug repurposing |
0.2 | 1 | 2023 | NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023 |
Methods — techniques the papers use, named apart from their topics
graph neural network · 1.4sequence representation learning · 0.8sequence-based learning · 0.7multi-head self-attention · 0.7
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2024 | Integrating sequence and graph information for enhanced drug-target affinity prediction
Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen |
Sci. China Inf. Sci. | 1 |
| 2024 | GINCM-DTA: A graph isomorphic network with protein contact map representation for potential use against COVID-19 and Omicron subvariants BQ.1, BQ.1.1, XBB.1.5, XBB.1.16
Guanxing Chen, Haohuai He, Qiujie Lv, Calvin Yu-Chian Chen |
Expert Syst. Appl. | 2 |
| 2023 | NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity predictionabstractMOTIVATION: Large-scale prediction of drug-target affinity (DTA) plays an important role in drug discovery. In recent years, machine learning algorithms have made great progress in DTA prediction by utilizing sequence or structural information of both drugs and proteins. However, sequence-based algorithms ignore the structural information of molecules and proteins, while graph-based algorithms are insufficient in feature extraction and information interaction. RESULTS: In this article, we propose NHGNN-DTA, a node-adaptive hybrid neural network for interpretable DTA prediction. It can adaptively acquire feature representations of drugs and proteins and allow information to interact at the graph level, effectively combining the advantages of both sequence-based and graph-based approaches. Experimental results have shown that NHGNN-DTA achieved new state-of-the-art performance. It achieved the mean squared error (MSE) of 0.196 on the Davis dataset (below 0.2 for the first time) and 0.124 on the KIBA dataset (3% improvement). Meanwhile, in the case of cold start scenario, NHGNN-DTA proved to be more robust and more effective with unseen inputs than baseline methods. Furthermore, the multi-head self-attention mechanism endows the model with interpretability, providing new exploratory insights for drug discovery. The case study on Omicron variants of SARS-CoV-2 illustrates the efficient utilization of drug repurposing in COVID-19. AVAILABILITY AND IMPLEMENTATION: The source code and data are available at https://github.com/hehh77/NHGNN-DTA. Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen |
Bioinform. | 1 |
| 2023 | 3D graph neural network with few-shot learning for predicting drug-drug interactions in scaffold-based cold start scenario
Qiujie Lv, Ziduo Yang, Haohuai He, Calvin Yu-Chian Chen |
Neural Networks | 4 |
| 2022 | 3DGT-DDI: 3D graph and text based neural network for drug-drug interaction predictionabstractMOTIVATION: Drug-drug interactions (DDIs) occur during the combination of drugs. Identifying potential DDI helps us to study the mechanism behind the combination medication or adverse reactions so as to avoid the side effects. Although many artificial intelligence methods predict and mine potential DDI, they ignore the 3D structure information of drug molecules and do not fully consider the contribution of molecular substructure in DDI. RESULTS: We proposed a new deep learning architecture, 3DGT-DDI, a model composed of a 3D graph neural network and pre-trained text attention mechanism. We used 3D molecular graph structure and position information to enhance the prediction ability of the model for DDI, which enabled us to deeply explore the effect of drug substructure on DDI relationship. The results showed that 3DGT-DDI outperforms other state-of-the-art baselines. It achieved an 84.48% macro F1 score in the DDIExtraction 2013 shared task dataset. Also, our 3D graph model proves its performance and explainability through weight visualization on the DrugBank dataset. 3DGT-DDI can help us better understand and identify potential DDI, thereby helping to avoid the side effects of drug mixing. AVAILABILITY: The source code and data are available at https://github.com/hehh77/3DGT-DDI. Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen |
Briefings Bioinform. | 1 |